<DOC>
	<DOCNO>NCT00001095</DOCNO>
	<brief_summary>To determine proportion patient treat amprenavir , zidovudine ( ZDV ) , stavudine ( D4T ) lamivudine ( 3TC ) whose HIV-1 RNA level remain level detection 96 week therapy . To determine proportion patient treat indinavir ( IDV ) , nevirapine ( NVP ) , 3TC , d4T whose HIV-1 RNA level decrease remain level detection , 96-week therapy period . To determine viral effect , safety , tolerability , pharmacokinetics amprenavir combination zidovudine , stavudine , lamivudine . [ AS PER AMENDMENT 2/27/98 : To determine proportion patient undetectable plasma HIV RNA , treatment baseline RNA cohort ( either detectable undetectable ) . To determine durability regimen estimate distribution time loss virologic suppression ( equivalently , time virologic failure ) , treatment baseline RNA cohort . ] This study allow patient successfully participate ACTG 347 trial involve amprenavir continue treatment amprenavir , ZDV , d4T , 3TC . Additionally , study provide patient whose HIV-1 RNA reduce undetectable level significant increase plasma level ( `` treatment failure '' ) opportunity change potentially active regimen include indinavir , nevirapine , lamivudine , stavudine .</brief_summary>
	<brief_title>A Study Three Anti-HIV Drug Combinations Patients Who Have Taken Amprenavir</brief_title>
	<detailed_description>This study allow patient successfully participate ACTG 347 trial involve amprenavir continue treatment amprenavir , ZDV , d4T , 3TC . Additionally , study provide patient whose HIV-1 RNA reduce undetectable level significant increase plasma level ( `` treatment failure '' ) opportunity change potentially active regimen include indinavir , nevirapine , lamivudine , stavudine . Patients HIV RNA le 500 copies/ml regimen contain amprenavir treat Arm A ; great equal 500 copy intolerant regimen contain amprenavir treat Arm B . Arm A : Amprenavir + ZDV + d4T + 3TC . Arm B : IND + NVP + 3TC + d4T . Patients enrol Arm A fail therapy may roll Arm B . Patients Arm B fail therapy discontinue study medication seek best available treatment . [ AS PER AMENDMENT 2/27/98 : Patients HIV RNA le 500 copies/ml currently triple therapy amprenavir + 3TC + ZDV ( d4T ZDV-intolerant ) treat ARM A . Patients HIV RNA great equal 500 copies/ml , intolerant regimen contain amprenavir previously enrol ACTG 347 elect receive treatment regimen amprenavir + ZDV ( d4T ) + 3TC IDV + NVP + 3TC + d4T regimen assign Arm C. Arm A : Amprenavir + ZDV* plus 3TC . Arm B : IDV** + NVP + 3TC + d4T*** . Arm C : Observation . Patients follow duration study . - Patients intolerant ZDV may elect receive d4T . **Patients intolerant IDV may take study-provided nelfinavir . ***Patients switch open-label IDV/NVP/3TC/d4T prior enrollment study intolerant study medication may enroll Arm B appropriate substitution intolerant study drug ( ) . Patients initially assign Arm A intolerant amprenavir fail therapy option receive Arm B therapy . Patients initially assign Arm B intolerant assign study drug may make appropriate antiretroviral substitution ( approval protocol chair ) . ]</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<mesh_term>Amprenavir</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Required : Chemoprophylaxis Pneumocystis carinii pneumonia ( patient CD4+ cell count less equal 200 cells/mm3 . Allowed : Topical and/or oral antifungal agent . Treatment , maintenance chemoprophylaxis approve agent opportunistic infection . Antibiotics . Systemic corticosteroid use 21 day less . Recombinant erythropoietin ( rEPO ) granulocytecolony stimulate factor ( GCSF , filgrastim ) . Regularly prescribed medication antipyretic , analgesic , allergy medication , antidepressant , sleep medication , oral contraceptive ( sole form contraception ) , megestrol acetate , testosterone . Alternative therapy vitamin , acupuncture , visualization technique . [ AS PER AMENDMENT 2/27/98 : Current use triple therapy amprenavir/3TC/ZDV ( d4T ) Arm A patient . Current use quadruple therapy IDV/NVP/3TC/d4T Arm B patient . ] Patients must : HIVpositive status . Successful response treatment ACTG 347 measure HIV RNA le 500 copies/ml ( Arm A ) OR unsuccessful response treatment ACTG 347 another regimen contain amprenavir OR increase plasma HIV RNA nadir value great 5,000 copies/ml least one log10 time ( Arm B ) OR intolerance regimen contain amprenavir . Consent patient le 18 year age . [ AS PER AMENDMENT 2/27/98 : Arm A patient must : HIV RNA le 500 copies/ml least one occasion within 60 day entry previously enrol ACTG 347 one follow category : currently receive amprenavir/3TC/ZDV ( d4T ) randomize monotherapy arm ACTG 347 receive openlabel amprenavir/3TC/ZDV ( d4T ) . Arm B patient must : Failed prior amprenavir therapy , whether ACTG 347 , i.e. , HIV RNA great equal 500 copies/ml least 16 week amprenavir confirm within 16 week OR treatment failure mandate early permanent discontinuation randomize ACTG 347 study drug define HIV RNA least one log 10 nadir ( least 5,000 copies/ml ) HIV RNA level baseline value 16 week amprenavir confirm within 16 week . Initially randomized triple therapy arm ACTG 347 two plasma HIV1 RNA value least 500 copies/ml take within 60 day prior study entry least 16 week apart initially receive openlabel amprenavir/3TC/ZDV ( d4T ) two HIV RNA level least 500 copies/ml , regardless duration treatment amprenavir/3TC/ZDV ( d4T ) . Documented intolerance reverse transcriptase inhibitor attempt nevirapine therapy allow . Arm C patient must : Previously enrol ACTG 347 elect receive treatment regimen amprenavir/3TC/ZDV ( d4T ) IDV/NVP/3TC/d4T . ] Prior Medication : Required : Amprenavir therapy [ AS PER AMENDMENT 2/27/98 : amprenavir therapy ( Arm A B patient ) ] . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Arm A : Inability tolerate amprenavir , ZDV , 3TC . Arm B : Inability tolerate d4T , NVP , 3TC . Active infection require acute treatment within 14 day prior study entry . Malignancy require systemic therapy ( patient minimal Kaposi 's sarcoma exclude provided require systemic therapy ) . [ AS PER AMENDMENT 2/27/98 : Patients follow condition symptom exclude : Arm A : Any detection plasma HIV RNA great 500 copies/ml subject switch triple therapy least 16 week . Inability tolerate amprenavir , ZDV ( d4T ) , 3TC . Malignancy require systemic therapy ( minimal Kaposi 's sarcoma allow provided systemic therapy require ) Arm A B patient . ] Concurrent Medication : Excluded : Nonprotocolspecified antiretroviral agent . Immunomodulators affect immunologic virologic index , systemic corticosteroid ( 21 day ) , thalidomide , cytokine . Concomitant use rifabutin and/or rifampin . Investigational drug without specific approval . Systemic cytotoxic chemotherapy . Oral astemizole , carbamazepine , dexamethasone , ketoconazole , itraconazole , phenobarbital , phenytoin , terfenadine , cisapride , triazolam , terfenadine , astemizole , midazolam . Prior Medication : [ AS PER AMENDMENT 2/27/98 : Excluded : Prior protease inhibitor therapy except amprenavir ( Arm A patient ) . Prior protease inhibitor therapy except amprenavir IDV ( Arm B patient ) . Excluded within 14 day prior entry : Investigational drug immunomodulators ( except amprenavir ) without specific consent protocol chair ( ) ( Arm A patient ) . Immunomodulators affect immunologic virologic index , systemic corticosteroid , thalidomide cytokine , unless approve protocol chair ( ) ( Arm B patient ) . Oral astemizole , carbamazepine , dexamethasone , ketoconazole , itraconazole , phenobarbital , phenytoin , terfenadine , cisapride , triazolam , midazolam , ergot alkaloid , drug contain derivative ergot alkaloid . ]</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Nevirapine</keyword>
	<keyword>Stavudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>VX 478</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
</DOC>